View Filing Data

Common stock, shares outstanding (in shares) | shares

Share-based compensation

$ 29,940

$ 0

24,957,309

Discount for Lack of Marketability [Member]

0.34

Volatility [Member]

Weighted Average Cost of Capital [Member]

0.9

Nonvoting Common Stock [Member]

0.275

Fair market value of non-voting shares at shares granted date

Share-based compensation

^[1]

$ 27,298

19,123

Withholding taxes on share-based compensation

$ 8,175

Number of common shares issued (in shares) | shares

4,922,353

Common stock, shares outstanding (in shares) | shares

4,922,353

[1]	Non-Voting Common Share Issuance

Summary of Significant Accounting Policies, Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Level 2 [Member]
Fair Value of Financial Instruments [Abstract]
Assets, fair value	$ 0
Liabilities, fair value	0
Level 3 [Member]
Fair Value of Financial Instruments [Abstract]
Assets, fair value	0
Liabilities, fair value	$ 0
Warrant liability, fair value		$ 7,673

Summary of Significant Accounting Policies, Deferred Offering Costs and Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred Offering Costs [Abstract]
Deferred offering costs	$ 5,232	$ 1,050
Recent Accounting Pronouncements [Abstract]
Accumulated deficit	(61,376)	$ (120,093)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] \| Accounting Standards Update 2014-09 [Member]
Recent Accounting Pronouncements [Abstract]
Accumulated deficit	$ 3,700

Risks and Uncertainties (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	12 Months Ended
	Aug. 15, 2018	Jul. 27, 2018	Aug. 15, 2018	Dec. 31, 2018	Dec. 31, 2017
Risks and Uncertainties [Abstract]
Working capital				$ 41,249
Initial public offering [Abstract]
Share price (in dollars per share)				$ 15.00
Net cash proceeds from initial public offering			$ 63,482	$ 68,714	$ 0
Initial Public Offering [Member]
Initial public offering [Abstract]
Number of common shares issued (in shares)		4,500,000
Share price (in dollars per share)		$ 15.00
Net cash proceeds from initial public offering		$ 57,543
Over-Allotment Option [Member]
Initial public offering [Abstract]
Number of common shares issued (in shares)	425,727		425,727
Share price (in dollars per share)	$ 15.00		$ 15.00
Net cash proceeds from initial public offering	$ 5,939

Revenues and Trade Receivables, Net, Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Revenue [Abstract]
Revenues	$ 16,824	$ 13,267	$ 13,928	$ 23,411	$ 12,194	$ 27,146	$ 11,142	$ 16,436	$ 67,430	$ 66,918
Manufacture and Supply Revenue [Member]
Revenue [Abstract]
Revenues									37,319	40,092
License and Royalty Revenue [Member]
Revenue [Abstract]
Revenues									24,699	23,133
Co-Development and Research Fees [Member]
Revenue [Abstract]
Revenues									5,184	3,693
Proprietary Product Sales, Net [Member]
Revenue [Abstract]
Revenues									$ 228	$ 0

Revenues and Trade Receivables, Net, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Revenues by Geographic Market [Abstract]
Revenues	$ 16,824	$ 13,267	$ 13,928	$ 23,411	$ 12,194	$ 27,146	$ 11,142	$ 16,436	$ 67,430	$ 66,918
United States [Member]
Revenues by Geographic Market [Abstract]
Revenues									64,565	63,710
Ex-United States [Member]
Revenues by Geographic Market [Abstract]
Revenues									$ 2,865	$ 3,208

Revenues and Trade Receivables, Net, Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accounts Receivable, Net [Abstract]
Accounts receivable	$ 6,610	$ 6,156
Other receivables	33	78
Less: allowance for bad debt	(58)	(55)	$ (108)
Less: sales-related allowances	(104)	0	$ 0
Trade and other receivables, net	$ 6,481	$ 6,179

Revenues and Trade Receivables, Net, Changes in Allowance for Bad Debts Account (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Allowance for Doubtful Accounts Receivable [Roll Forward]
Allowance for doubtful accounts at beginning of year	$ 55	$ 108
Additions charged to bad debt expense	53	0
Write-downs charged against the allowance	(50)	0
Recoveries of amounts previously reserved	0	(53)
Allowance for doubtful accounts at end of year	$ 58	$ 55

Revenues and Trade Receivables, Net, Accounts Receivable Allowances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues and Trade Receivables, Net [Roll Forward]
Beginning balance	$ 0	$ 0
Provision related to sales in 2018	104	0
Credits and payments	0	0
Ending balance	$ 104	$ 0

Revenues and Trade Receivables, Net, Concentration of Major Customers (Details) - Indivior [Member]	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue [Member]
Customer Concentration [Abstract]
Concentrations of risk	89.00%	88.00%
Receivables [Member]
Customer Concentration [Abstract]
Concentrations of risk	78.00%	93.00%

Material Agreements (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended		180 Months Ended	182 Months Ended
Material Agreements (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Feb. 20, 2019
Agreements [Abstract]
Revenues	$ 16,824	$ 13,267	$ 13,928	$ 23,411	$ 12,194	$ 27,146	$ 11,142	$ 16,436	$ 67,430	$ 66,918
Commercial Exploitation Agreement with Indivior [Member]
Agreements [Abstract]
License agreement term									7 years
Automatic renewal period of agreement									1 year
Commercial Exploitation Agreement with Indivior [Member] \| Minimum [Member]
Agreements [Abstract]
Notice period of intent not to renew agreement									1 year
Supplemental Agreement with Indivior [Member]
Agreements [Abstract]
Revenues												$ 40,750
Contingent payments receivable in the future	34,250								$ 34,250		$ 34,250
Supplemental Agreement with Indivior [Member] \| Maximum [Member]
Agreements [Abstract]
Contingent payments receivable in the future	75,000								75,000		75,000
Supplemental Agreement with Indivior Performance or Event-Based Milestones [Member]
Agreements [Abstract]
Contingent payments receivable in the future	33,000								33,000		33,000
Supplemental Agreement with Indivior Additional Process Patent Rights to the Company [Member]
Agreements [Abstract]
Contingent payments receivable in the future	1,250								1,250		1,250
License Agreement with Sunovion Pharmaceuticals, Inc. [Member]
Agreements [Abstract]
Revenues											18,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member]
Agreements [Abstract]
Revenues											13,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member] \| Maximum [Member]
Agreements [Abstract]
Contingent payments receivable in the future	$ 45,000								45,000		45,000
License Agreement with Sunovion Pharmaceuticals, Inc. Upfront [Member]
Agreements [Abstract]
Revenues											$ 5,000
Agreement to Terminate CLA with KemPharm [Member]
Agreements [Abstract]
Revenues									$ 0	$ 0

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory [Abstract]
Raw material	$ 1,283	$ 725
Packaging material	2,975	2,225
Finished goods	1,183	1,064
Total inventory	$ 5,441	$ 4,014

Property and Equipment, net (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Less: accumulated depreciation and amortization

$ 47,398

$ 45,465

(35,191)

(32,005)

Total property and equipment, net

12,207

13,460

Depreciation and amortization

3,186

3,750

Machinery [Member]

Machinery [Member] | Minimum [Member]

$ 20,681

20,056

Machinery [Member] | Maximum [Member]

3 years

Furniture and Fixtures [Member]

15 years

Furniture and Fixtures [Member] | Minimum [Member]

$ 1,150

1,109

Furniture and Fixtures [Member] | Maximum [Member]

3 years

Leasehold Improvements [Member]

15 years

Computer, Network Equipment and Software [Member]

^[1]

$ 21,333

21,271

Computer, Network Equipment and Software [Member] | Minimum [Member]

$ 2,579

2,108

Computer, Network Equipment and Software [Member] | Maximum [Member]

3 years

Construction in Progress [Member]

7 years

$ 1,655

$ 921

[1]	Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.

Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Identifiable Intangible Assets [Abstract]
Intangible assets, gross	$ 2,867	$ 2,867
Less: accumulated amortization	(2,663)	(2,613)
Intangible assets, net	204	254
Amortization expense	50	51
Estimated Annual Amortization Expense [Abstract]
2019	50
2020	50
2021	50
2022	50
Purchase Technology-based Intangible [Member]
Identifiable Intangible Assets [Abstract]
Intangible assets, gross	2,358	2,358
Purchased Patent [Member]
Identifiable Intangible Assets [Abstract]
Intangible assets, gross	$ 509	$ 509

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accrued Expenses [Abstract]
Accrued Compensation	$ 3,604	$ 3,805
Accrued withholding tax for share-based compensation	2,515	0
Real estate and personal property taxes	388	372
Accrued distribution expenses	481	0
Other	207	225
Total accrued expenses	$ 7,195	$ 4,402

Loans Payable (Details) $ in Thousands	1 Months Ended	12 Months Ended
Loans Payable (Details) $ in Thousands	Mar. 31, 2017 USD ($)	Dec. 31, 2018 USD ($) Payment	Dec. 31, 2017 USD ($)
Line of Credit Facility [Abstract]
Loans payable, current		$ 4,600	$ 0
Amortization expense, deferred debt issuance costs and debt discounts		1,696	1,860
Unamortized deferred debt issuance cost and deferred debt discounts		2,797	4,493
Perceptive Credit Opportunities Fund, LP [Member] \| Line of Credit [Member]
Line of Credit Facility [Abstract]
Borrowing amount		45,000
Additional borrowing capacity		5,000
Drew down amount	$ 5,000
Credit facility, maximum borrowing capacity		$ 50,000
Debt maturity date		Dec. 16, 2020
Debt instrument base rate		2.00%
Debt instrument variable interest rate		9.75%
Loans payable, current		$ 4,600
Financial covenant requirement, Consecutive period for maintaining minimum revenues		12 months
Warrant to purchase senior common equity interest ratio to fully diluted common units		4.50%
Perceptive Credit Opportunities Fund, LP [Member] \| Line of Credit [Member] \| Minimum [Member]
Line of Credit Facility [Abstract]
Debt instrument effective interest rate		11.75%
Financial covenant requirement, monthly cash balance		$ 4,000
Perceptive Credit Opportunities Fund, LP [Member] \| Line of Credit [Member] \| May 2019 [Member]
Line of Credit Facility [Abstract]
Frequency of periodic principal payment		Monthly
Number of loan principal payments \| Payment		7
Monthly principal payment amount		$ 550
Perceptive Credit Opportunities Fund, LP [Member] \| Line of Credit [Member] \| August 2019 [Member]
Line of Credit Facility [Abstract]
Frequency of periodic principal payment		Monthly
Monthly principal payment amount		$ 750
Perceptive Credit Opportunities Fund, LP [Member] \| Line of Credit [Member] \| LIBOR [Member]
Line of Credit Facility [Abstract]
Term of variable rate		1 month
White Oaks Global Advisors, LLC [Member] \| Line of Credit [Member]
Line of Credit Facility [Abstract]
Payment of existing debt obligation			$ 37,500

Warrants (Details) $ / shares in Units, $ in Thousands	12 Months Ended
Warrants (Details) $ / shares in Units, $ in Thousands	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($)
Warrants [Abstract]
Cash received for warrant exercise	$ 116	$ 24
Initial price of common stock offered (in dollars per share) \| $ / shares	$ 15.00
Warrant Liability [Roll Forward]
Balance as of beginning of period	$ 7,673	6,550
Change in fair value recognized	5,278	1,123
Exercise of warrants	(12,951)
Balance as of end of period	$ 0	$ 7,673
Discount Rate [Member]
Warrants [Abstract]
Measurement input of warrants		0.265
Volatility Rate [Member]
Warrants [Abstract]
Measurement input of warrants		0.9
Perceptive Credit Opportunities Fund, LP [Member]
Warrants [Abstract]
Number of shares received upon automatic exercise of warrant (in shares) \| shares	863,400
Cash received for warrant exercise	$ 116
Perceptive Credit Opportunities Fund, LP [Member] \| Line of Credit [Member]
Warrants [Abstract]
Warrant to purchase senior common equity interest ratio to fully diluted common units	4.50%
Purchase price of warrant within first year of the loan	$ 3,000
Purchase price of warrant after first year	5,000
Warrant liability, fair value	$ 5,800

Asset Retirement Obligation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Asset Retirement Obligation [Abstract]
Depreciation expense related to ARO	$ 27	$ 25
Asset Retirement Obligation [Roll Forward]
Balance at beginning of period	1,081	959
Additions	5	0
Accretion	130	122
Balance at ending of period	$ 1,216	$ 1,081

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Numerator [Abstract]
Net loss	$ (13,944)	$ (15,038)	$ (36,493)	$ 4,099	$ (10,040)	$ 8,451	$ (5,897)	$ (1,457)	$ (61,376)	$ (8,943)
Denominator [Abstract]
Weighted-average number of common shares - basic and diluted (in shares)									20,725,526
Loss per common share - basic and diluted (in dollars per share)	$ (0.56)	$ (0.64)	$ (1.90)	$ 0.27					$ (2.96)
Stock Options [Member]
Dilutive Instruments [Abstract]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)									1,033,492
Unvested Restricted Stock Units [Member]
Dilutive Instruments [Abstract]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)									205,175

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Share-Based Compensation (Details)
$ / shares in Units, $ in Thousands

7 Months Ended

12 Months Ended

Dec. 31, 2018

USD ($)

$ / shares

Dec. 31, 2018

USD ($)

Plan

Period

$ / shares

Dec. 31, 2017

USD ($)

Jun. 30, 2018

$ 29,940

$ 0

Common stock, shares outstanding (in shares) | shares

24,957,309

Valuation Assumptions for Determination of Fair Value [Abstract]

Shares available for grant (in shares) | shares

2,900,000

Share price (in dollars per share)

$ 15.00

Manufacturing and Supply [Member]

Research and Development [Member]

$ 414

Selling, General and Administrative [Member]

2,583

Discount for Lack of Marketability [Member]

$ 26,943

Valuation Assumptions for Determination of Fair Value [Abstract]

Valuation Assumptions for Determination of Fair Value [Abstract]

0.34

Volatility [Member]

Weighted Average Cost of Capital [Member]

0.9

Valuation Assumptions for Determination of Fair Value [Abstract]

Nonvoting Common Stock [Member]

0.275

^[1]

$ 27,298

Common stock, shares outstanding (in shares) | shares

4,922,353

Fair market value of non-voting shares at shares granted date | $

$ 19,123

Withholding taxes on share-based compensation | $

$ 8,175

Number of common shares issued (in shares) | shares

4,922,353

Performance Units [Member]

Number of performance units plans | Plan

Restricted Stock Units [Member]

$ 1,085

^[2]

Unvested at Plan adoption (in shares) | shares

Service period

2 years

Number of Units [Roll Forward]

Granted (in shares) | shares

265,000

Vested (in shares) | shares

(60,000)

Unvested, at end of period (in shares) | shares

205,000

Weighted Average Grant Date Fair Value Per Share [Abstract]

Unvested at Plan adoption (in dollars per share)

$ 0

Vested (in dollars per share)

14.83

15.03

Unvested, Balance at end of period (in dollars per share)

$ 14.77

Grant date fair value | $

$ 896

Compensation Cost Not yet Recognized [Abstract]

Unrecognized stock-based compensation expense | $

$ 2,568

Unrecognized compensation cost, recognition period

3 years

Weighted average grant date fair value (in dollars per share)

$ 14.83

Restricted Stock Units [Member] | Senior Management and Board [Member]

Restricted Stock Units [Member] | key Employees [Member]

2 years

3 years

Stock Options [Member]

^[2]

$ 1,557

Weighted Average Grant Date Fair Value Per Share [Abstract]

Service period

3 years

Outstanding at beginning of period (in shares) | shares

$ 10.83

Number of Options [Roll Forward]

Granted (in shares) | shares

1,033,000

Exercised, Forfeited, Expired (in shares) | shares

Outstanding at end of period (in shares) | shares

1,033,000

Vested or expected to vest at end of period (in shares) | shares

962,000

Exercisable at end of period (in shares) | shares

87,000

Weighted Average Exercise Price [Abstract]

Outstanding at end of period (In dollars per share)

$ 14.72

14.72

$ 14.72

Vested or expected to vest at end of period (in dollars per share)

14.72

Exercisable at end of period (in dollars per share)

$ 15.02

Weighted Average Remaining Contractual Term in Years [Abstract]

Granted

9 years 6 months 18 days

Outstanding at end of period

9 years 6 months 18 days

Vested or expected to vest at end of period

9 years 6 months 18 days

Exercisable at end of period

9 years 6 months 22 days

Aggregate Intrinsic Value [Abstract]

Granted | $

$ 0

Outstanding at end of period | $

$ 0

Vested or expected to vest at end of period | $

Exercisable at end of period | $

$ 0

Stock options grant, exercise price (in dollars per share)

$ 14.72

Term of award

10 years

Share price (in dollars per share)

$ 6.30

Number of vesting periods | Period

Fair Value Assumptions [Abstract]

Expected dividend yield

0.00%

Expected volatility

90.00%

Compensation Cost Not yet Recognized [Abstract]

Unrecognized stock-based compensation expense | $

$ 8,845

Unrecognized compensation cost, recognition period

2 years 7 months 6 days

Weighted average grant date fair value (in dollars per share)

$ 10.83

Stock Options [Member] | Minimum [Member]

Weighted Average Exercise Price [Abstract]

6.54

Stock options grant, exercise price (in dollars per share)

$ 6.54

Fair Value Assumptions [Abstract]

Expected term (years)

5 years 9 months 18 days

Risk-free rate

2.80%

Stock Options [Member] | Maximum [Member]

Weighted Average Exercise Price [Abstract]

$ 18.67

Stock options grant, exercise price (in dollars per share)

$ 18.67

Fair Value Assumptions [Abstract]

Expected term (years)

6 years 1 month 6 days

Risk-free rate

2.90%

Stock Options [Member] | Senior Management and Board [Member]

Stock Options [Member] | key Employees [Member]

3 years